-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 26, North China Pharmaceutical issued an announcement stating that it had recently received the "Notice of Approval of Supplementary Drug Application" for Amoxicillin Sodium and Clavulanate Potassium for Injection (0.
3g, 0.
6g, 1.
2g) approved by the National Medical Products Administration.
, The drug passed the consistency evaluation of the quality and efficacy of generic drugs (hereinafter referred to as "consistency evaluation")
.
Amoxicillin is a penicillin-type broad-spectrum β-lactam antibiotic.
It has strong antibacterial and bactericidal effects on most pathogenic gram-positive and gram-negative bacteria, but amoxicillin is susceptible to resistance The β-lactamase produced by bacteria is degraded; Clavulanic acid is an irreversible β-lactamase inhibitor, which can inactivate β-lactamase and reduce the degree of amoxicillin hydrolysis by β-lactamase.
To reduce the chance of drug resistance
.
Amoxicillin and clavulanate potassium compound preparations are widely used clinically to treat upper respiratory tract infections, lower respiratory tract infections, genitourinary tract infections, skin and soft tissue infections and other infections caused by sensitive bacteria